Efficacy and safety of a once‐daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective: To test the efficacy and safety of a once‐daily formulation of EGb 761 in the treatment of patients with dementia with neuropsychiatric features. Methods: Multi‐centre trial of 410 outpatients with mild to moderate dementia (Alzheimer's disease, vascular dementia or mixed form) scoring between 9 and 23 on the SKT cognitive test battery, at least five on the Neuropsychiatric Inventory (NPI) and three or higher in at least one item of the NPI. Patients were randomly allocated to double‐blind treatment with 240 mg of EGb 761 or placebo once daily for 24 weeks. Primary outcomes were the changes from baseline in the SKT total score and the NPI total score. The Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (ADCS‐CGIC), Activities of Daily Living International Scale (ADL‐IS), NPI distress score, DEMQOL‐Proxy quality‐of‐life scale and Verbal Fluency Test were secondary outcomes. Results: At endpoint, patients treated with EGb 761 (n = 202) improved by −1.4 (95% confidence interval −1.8; −1.0) points on the SKT and by −3.2 (−4.0; −2.3) on the NPI total score, whereas those receiving placebo (n = 202) deteriorated by +0.3 (−0.1; 0.7) on the SKT and did not change on the NPI total score (−0.9; 0.9). Both drug‐placebo comparisons were significant at p < 0.001. EGb 761 was significantly superior to placebo with respect to all secondary outcome measures. Adverse event rates were similar for both treatment groups. Conclusions: EGb 761, 240 mg once‐daily, was found significantly superior to placebo in the treatment of patients with dementia with neuropsychiatric symptoms. Copyright © 2010 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
Self-citationMixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992 · cited 2×
“Taking into account that the majority of patients with dementia have both Alzheimer-type and vascular brain pathology (Snowdon et al., 1997; Neuropathology Group of the MRC-CFAS, 2001; Korczyn, 2002; Schneider et al., 2007; Matthews et al., 2009), patients with either”
BackgroundBrain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943 · cited 1×
“…domain are in the same range as corresponding drug-placebo differences reported for cholinesterase inhibitors, e.g. 1.6–2.9 points on the ADAS-cog (Corey-Bloom et al., 1998; Rösler et al., 1999) and 8–27% in response rates (Rogers et al., 1998; Rösler et al., 1999; Wilcock et al., 2000).”
ResultInfluentialMatthews, F. E., Brayne, C., Lowe, J., McKeith, I., Wharton, S. B., & Ince, P. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000180 · Cited by 279 · cited 4×
“Taking into account that the majority of patients with dementia have both Alzheimer-type and vascular brain pathology (Snowdon et al., 1997; Neuropathology Group of the MRC-CFAS, 2001; Korczyn, 2002; Schneider et al., 2007; Matthews et al., 2009), patients with either”
BackgroundInfluentialMixed Dementia—the Most Common Cause of Dementia
KORCZYN, A. D. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04807.x · Cited by 219
Self-citation
Cited by
Tan, M.-S., Yu, J.-T., Tan, C.-C., Wang, H.-F., Meng, X.-F., Wang, C., Jiang, T., Zhu, X.-C., & Tan, L. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140837 · Cited by 253
Andrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. D. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092313 · Cited by 240
Liu, X., Hao, W., Qin, Y., Decker, Y., Wang, X., Burkart, M., Schötz, K., Menger, M. D., Fassbender, K., & Liu, Y. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.01.011 · Cited by 149
Liu, H., Ye, M., & Guo, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01688 · Cited by 116
Metadata
- Authors
- Ihl, R., Bachinskaya, N., Korczyn, A. D., Vakhapova, V., Tribanek, M., Hoerr, R., & Napryeyenko, O.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2010-12-07
- Volume
- 26
- Issue
- 11
- Pages
- 1186-1194
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W2033307745
- Cited by
- 139
- References
- 8
- FWCI
- 22.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of a once‐daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. https://app.cochat.ai/papers/10.1002/gps.2662
- The paper
- Ihl, R., Bachinskaya, N., Korczyn, A. D., Vakhapova, V., Tribanek, M., Hoerr, R., & Napryeyenko, O. (2011). Efficacy and safety of a once‐daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.2662
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.